Evidence map›Paper›PMID 42377740›Full record

ReviewAdvances in therapy2026

Management of Persistent Storage Symptoms and Overactive Bladder in Men Diagnosed with Benign Prostatic Hyperplasia: A Narrative Review.

Bradley C Gill, Matt T Rosenberg, Steven A Kaplan, Lori B Lerner

Abstract readReview
In one paragraph

Review in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Bradley C Gill *Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, USA. bradgillmd@gmail.com.
Matt T Rosenberg *Mid-Michigan Health Centers, Jackson, MI, USA. matttoren@yahoo.com.
Steven A KaplanDepartment of Urology, Icahn School of Medicine at Mount Sinai, Mount Sinai, New York, NY, USA.
Lori B LernerVA Boston Healthcare System, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Benign prostatic hyperplasia (BPH) and overactive bladder (OAB) both cause lower urinary tract symptoms (LUTS) in men. Ongoing urgency, frequency, and nocturia despite effective BPH management may indicate coexistence of primary OAB in many individuals. A literature search was conducted to support a narrative review aimed at enhancing awareness that urinary symptoms in men should not be attributed solely to either BPH or OAB, as LUTS have numerous etiologies, and OAB and BPH are both prevalent among men. Owing to different etiologies of BPH and OAB, LUTS in men may not be adequately addressed with a single treatment. BPH medications primarily target voiding-related symptoms, and storage-related symptoms may persist. Storage-related symptoms (i.e., OAB) are generally the most bothersome and frequently reported element of LUTS, reducing quality of life, and studies suggest that OAB in men is inadequately addressed. Furthermore, men with both BPH and OAB seldom receive treatment for OAB after BPH management, if at all. Thus, men may benefit from clinicians prescribing OAB medication alongside those for BPH. This approach has been evaluated in clinical trials, some of which have shown improvements in OAB symptoms among men with BPH, without introducing additional safety concerns. Proactive discussions about symptoms, especially in the primary care setting, may help facilitate timely and effective treatment of this common issue. There are established OAB treatments that can be safely and successfully combined with BPH management to effectively address persistent storage symptoms and complex urinary symptoms in men.

Indexed as

Lower Urinary Tract SymptomsProstatic HyperplasiaUrinary Bladder, OveractiveAdrenergic beta-3 Receptor AgonistsHumansMaleQuality of LifeAdrenergic beta-3 Receptor AgonistsAlpha-blockersAnticholinergicsBenign prostatic hyperplasiaBeta-3 adrenergic receptor agonistsCombination drug therapyLower urinary tract symptomsMirabegronOveractive bladderPrimary careVibegron

Identifiers

PMID42377740
PMCPMC13499721

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.